论文部分内容阅读
许多白血病或骨髓发育不良综合征患者在异基因骨髓移植后疾病复发。试图应用化疗药物或第二次骨髓移植诱使持久缓解,通常不能成功。骨髓移植后的嵌合体状态,提供了一种新的治疗方法的机会,例如选择性刺激供髓造血,或增强移植物抗白血病(GVL)反应。 作者应用Filgrastim(粒细胞集落刺激因子)治疗了7例异基因骨髓移植后于40～360天内复发的白血病患者(其中1例为慢粒急变,5例为急性髓性
Many patients with leukemia or myelodysplastic syndrome relapse after allogeneic bone marrow transplantation. Attempting to induce long-term remission with chemotherapeutic drugs or a second bone marrow transplant usually fails. Chimerism status after bone marrow transplantation offers a new opportunity for therapeutic approaches such as selective stimulation of myeloid blood or enhanced graft versus leukemia (GVL) responses. The authors used Filgrastim (granulocyte colony-stimulating factor) to treat leukemia that relapsed within 40 to 360 days after allogeneic bone marrow transplantation in 7 patients (1 was chronic myo- basal, 5 were acute myeloid